51
|
Le Scodan R, Mornex F, Partensky C, Mercier C, Valette PJ, Ychou M, Bibeau F, Scoazec JY. Chimioradiothérapie préopératoire des adénocarcinomes du pancréas : évaluation anatomopathologique de l’efficacité thérapeutique. Cancer Radiother 2011; 15:97-105. [DOI: 10.1016/j.canrad.2010.06.019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2010] [Revised: 05/26/2010] [Accepted: 06/16/2010] [Indexed: 12/20/2022]
|
52
|
|
53
|
Chefrour M, Fischel JL, Formento P, Giacometti S, Ferri-Dessens RM, Marouani H, Francoual M, Renée N, Mercier C, Milano G, Ciccolini J. Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines. J Chemother 2010; 22:129-33. [PMID: 20435574 DOI: 10.1179/joc.2010.22.2.129] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The combination of capecitabine and the tyrosine kinase inhibitor erlotinib has recently been tested in patients with gemcitabine-refractory pancreatic tumors, with limited success. To understand this lack of efficacy, we studied the molecular effects of these agents in Capan-1 and Capan-2 human pancreatic resistant cancer cells. Erlotinib up-regulated thymidine phosphorylase (+50%) and downregulated dihydropyrimidine dehydrogenase (+55%) in a cell-dependent manner, thus suggesting that the combination should result in synergism. However, only mild additivity was achieved at best when combining both drugs, and several sequences tested even led to strong antagonism. Further experiments were performed to understand this lack of efficacy. We found that the fluoropyrimidine down-regulated EGFR expression by 30%, an unexpected finding resulting in a possible reduction in efficacy when cells were subsequently exposed to erlotinib. We also observed marked drug-induced over-expression of both cytosolic and extracellular vascular endothelial growth factor (VEGF) secretion, thus possibly triggering proliferation. These preliminary findings strongly suggest that these observations could be new mechanisms in the development of acquired drug resistance in pancreatic cancer cells.
Collapse
|
54
|
Mercier C, Yang C, Dahan L, Ciccolini J, Bagarry D, Seitz JF, Favre RG, Lacarelle B, Duffaud F. 5-fluorouracil in head and neck cancer patients: A population pharmacokinetics study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
55
|
Peyrade F, Mercier C, Chamorey E, Lallemant B, Alfonsi M, Righini C, Guelfucci B, Beltran M, Zanaret M, Dassonville O. Prognostic index for safety and compliance of docetaxel/ciplatin/5-fluorouracil (TPF) induction followed by radiochemotherapy (RT-CT) in 203 patients (pts) with unresectable squamous cell carcinoma of the head and neck (USCCHN). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e16001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
56
|
Dahan L, Ciccolini J, Mercier C, Duluc M, Ries P, Norguet E, Oculi C, Evrard A, Ouafik L, Seitz JF. Treatment failure upon gemcitabine intake: Is cytidine deaminase extensivity the ideal culprit? J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14558] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
57
|
Scavarda D, Imada V, Rolland AC, Lortie A, Mercier C, Carmant L. Peri-insular hemispherotomy in children: a single institution experience. Minerva Pediatr 2010; 62:1-7. [PMID: 20212393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The objective of this paper is to evaluate our experience in performing peri-insular hemispherotomy in refractory epileptic children. First, we address the history of hemispheric surgeries for epilepsy and then we compare our results to the medical literature in term of seizure control and complications. Between 1993 and 2007, 14 children who suffered from refractory hemispheric epilepsy underwent a peri-insular hemispherotomy. All children's charts were reviewed in a retrospective manner. Age at onset of epilepsy, imaging studies, cause of refractory epilepsy, electroencephalography findings, type of epileptic seizure, number of antiepileptic drugs (AED), preoperative neuropsychological evaluation and surgical outcome with regard to the children's seizure activity were analyzed. Nine boys and 5 girls were enrolled in this study. The mean age at onset of epilepsy was 16 months (range birth-5 years). All the children presented complex partiel seizures. Seizure frequency varied from 5 to 100 a day. The average delay prior to the hemispherotomy was 83 months (range 12-226 months). Mean age at the time of the surgery was 8.4 years (range 1.7-18 years). We performed 9 peri-insular hemispherotomies on the right side and 5 on the left. There were no reported surgical complications in this series. 10 children are seizure free (72%). Peri-insular hemispherotomy must be considered as a safe and very efficient therapeutic approach for children suffering from hemispheric refractory epilepsy. Peri-insular hemispherotomies are procedures where pathology and surgical technique interact narrowly. Acquired pathologies had better results than developmental ones.
Collapse
|
58
|
Mercier C, Bret P, Bret MC, Queuille E. Enquête observationnelle de prescription de la clozapine au centre hospitalier Charles-Perrens à Bordeaux, plus de 15 ans après l’AMM en France. Encephale 2009; 35:321-9. [DOI: 10.1016/j.encep.2008.10.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2007] [Accepted: 10/13/2008] [Indexed: 11/24/2022]
|
59
|
Le Scodan R, Mornex F, Girard N, Mercier C, Valette PJ, Ychou M, Bibeau F, Roy P, Scoazec JY, Partensky C. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009; 20:1387-96. [DOI: 10.1093/annonc/mdp015] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
|
60
|
Mercier C, Brunet C, Yang C, Dupuis C, Bagarry-Liegey D, Duflo S, Giovanni A, Zanaret M, Lacarelle B, Duffaud F, Ciccolini J. Pharmacoeconomic study in head and neck cancer patients: Impact of prospective DPD deficiency screening with 5-fluorouracil (5-FU) dose tailoring on toxicities-related costs. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6515] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6515 Background: Dihydropyrimidine dehydrogenase (DPD) plays a pivotal role in the detoxification of 5-FU. We studied the impact of screening DPD impairment in head and neck cancer (HNC) patients, both on reduction of drug-related toxicities and as a pharmacoeconomic endpoint. Methods: A total of 148 consecutive patients with HNC treated with 5-FU+platinum were monitored. Seventy-four patients (Arm A - before 2006) were treated with standard dosage, whereas 74 other patients (Arm B - after 2006) had their DPD status phenotypically evaluated prior to receiving 5-FU, with subsequent dose reduction if DPD deficiency were suspected. Severe toxicities and response were compared. Additionally, direct and indirect costs required to manage the treatment-related toxicities and to establish DPD status were calculated. Results: Sepsis was observed in 16.2% of patients treated with standard dosage. In Arm B, DPD deficiency was suspected in 35% of the patients and 5-FU dosage was subsequently reduced. Consequently, only 1.8% of them experienced sepsis. Of note, response rates were comparable between Arm A and B (62 vs 61%, p>0.05), thus demonstrating that 5-FU dose tailoring did not negatively impact on treatment efficacy, while reducing the occurrence of severe toxicities. Managing toxicities required an average 23-days of extra-hospitalization (4–96 days), including an average 1.6-day stay in ICU. No patients from Arm B had to stay in ICU. Drugs required for managing toxicities cost an average of $339 per patient (Arm A) and was reduced down to $38 per patient (Arm B). Similarly, mean extra-hospitalization cost was $5,940/patient in Arm A and $245/patient in Arm B. Testing DPD cost $49/patient in Arm B. Conclusions: Developing an adaptative dosing strategy based upon DPD status evaluation led to a dramatic reduction of the incidence of 5-FU-related severe toxicities, while maintaining optimal efficacy. Subsequently, extra-cost (medication + hospitalization costs) required to manage the toxicities fell down from $6,279 to $294/patient. Overall, this study advocates that systematic screening for DPD deficiency could be cost-efficient in the setting of 5-FU-based chemotherapies, with a reduction of 95% of the extra-costs. No significant financial relationships to disclose.
Collapse
|
61
|
Bonnefoy E, Steg PG, Boutitie F, Dubien PY, Lapostolle F, Roncalli J, Dissait F, Vanzetto G, Leizorowicz A, Kirkorian G, Mercier C, McFadden EP, Touboul P. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J 2009; 30:1598-606. [PMID: 19429632 DOI: 10.1093/eurheartj/ehp156] [Citation(s) in RCA: 152] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
AIMS The CAPTIM (Comparison of primary Angioplasty and Pre-hospital fibrinolysis In acute Myocardial infarction) study found no evidence that a strategy of primary angioplasty was superior in terms of 30-day outcomes to a strategy of pre-hospital fibrinolysis with transfer to an interventional facility in patients managed early at the acute phase of an acute myocardial infarction. The present analysis was designed to compare both strategies at 5 years. METHODS AND RESULTS The CAPTIM study included 840 patients managed in a pre-hospital setting within 6 h of an acute ST-segment elevation myocardial infarction. Patients were randomized to either a primary angioplasty (n = 421) or a pre-hospital fibrinolysis (rt-PA) with immediate transfer to a centre with interventional facilities (n = 419). Long-term follow-up was obtained in blinded fashion from 795 patients (94.6%). Using an intent-to-treat analysis, all-cause mortality at 5 years was 9.7% in the pre-hospital fibrinolysis group when compared with 12.6% in the primary angioplasty group [HR 0.75 (95% CI, 0.50-1.14); P = 0.18]. For patients included within 2 h, 5 year mortality was 5.8% in the pre-hospital fibrinolysis group when compared with 11.1% in the primary angioplasty group [HR 0.50 (95% CI, 0.25-0.97); P = 0.04], whereas it was, respectively, 14.5 and 14.4% in patients included after 2 h [HR 1.02, (95% CI 0.59-1.75), P = 0.92]. CONCLUSION The 5-year follow-up is consistent with the 30-day outcomes of the trial, showing similar mortality for primary percutaneous coronary intervention and a policy of pre-hospital lysis followed by transfer to an interventional center. In addition, for patients treated within 2 h of symptom onset, 5-year mortality was lower with pre-hospital lysis.
Collapse
|
62
|
Rossignol E, Lortie A, Thomas T, Bouthiller A, Scavarda D, Mercier C, Carmant L. Vagus nerve stimulation in pediatric epileptic syndromes. Seizure 2008; 18:34-7. [PMID: 18657451 DOI: 10.1016/j.seizure.2008.06.010] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2007] [Revised: 06/05/2008] [Accepted: 06/13/2008] [Indexed: 10/21/2022] Open
Abstract
Vagal nerve stimulation (VNS) has shown promising results in various cohorts of non-surgical refractory epilepsy in adults and children. However studies report a significant delay between implantation and clinical response. We describe a cohort of 28 children and adolescents prospectively followed, classified by epileptic syndromes and treated with VNS using a 6-week rapid ramping protocol between January 2000 and March 2005. Our cohort showed favorable outcome within 6 months which was sustained at 24 months: 68% (19/28) showing >or=50% reduction in seizure frequency, including 14% (4/28) who became seizure-free. VNS was particularly efficacious in children with cryptogenic generalized and partial epilepsies. Although adverse events occurred in 68% (19/28) of patients, most were transient. In conclusion, rapid ramping is associated with an early and lasting response in most children but with a slightly higher side-effect rate.
Collapse
|
63
|
Gagné M, Hétu S, Reilly K, Dubé J, Mercier C. Is there a relationship between altered M1 excitability of a stump muscle representation and phantom sensations? Brain Stimul 2008. [DOI: 10.1016/j.brs.2008.06.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
64
|
Mercier C, Yang C, Rosca C, Ciccolini J, Padovani L, Bagarry-Liegey D, Dupuis C, Lacarelle B, Zanaret M, Duffaud F, Favre R. Prospective phenotypic screening for DPD deficiency prior to 5-FU administration: Decrease in toxicity, not in efficacy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14556] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
65
|
Padovani L, Dahan L, Blesius A, Mercier C, Duluc M, Giacometti S, Duffaud F, Favre R, Seitz J, Ciccolini J. Anticipating gemcitabine-related severe/lethal toxicities: A feasibility study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
66
|
Poulain P, Mercier C. [Fetal assessment of the labor admission in low risk pregnancies]. JOURNAL DE GYNECOLOGIE, OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION 2008; 37 Suppl 1:S16-S22. [PMID: 18191911 DOI: 10.1016/j.jgyn.2007.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The assessment of fetal well-being at the beginning of labor must lead to an appropriate monitoring, adapted to the present risks. Even if some medical events are unforeseeable, three ways of reflexions get clear: abnormal maternofetal signs at the admission indicate the need for an increased monitoring (NP5); the reading of the medical file could reveal a high-risk pregnancy; at least, the realization of electronic fetal heart rate monitoring for any woman at the beginning of the labor is recommended: in case of normality, it remains a good criterion of a fetal good health. In this context of admission, there is no evidence supporting that other techniques (amnioscopy, acoustic test, echography, Doppler, etc.) could be beneficial in low-risk women and be recommended (NP5). Research is to be continued in this field.
Collapse
|
67
|
Boissonnat P, Noel-Baron F, Gaillard S, Mercier C, Roussoulieres A, Sebbag L, Bastien O, Redonnet M, Lelong B, Mattei MF, Mouly-Bandini A, Treilhaud M, Pattier S, Sirinelli A, Epailly E, Thiranos JC, Varnous S, Billes MA. 467: The Impact on Renal Function of an Early Reduction of Cyclosporine in De Novo Cardiac Transplant under MMF: Results of a French Multicenter Prospective Randomized Study. J Heart Lung Transplant 2008. [DOI: 10.1016/j.healun.2007.11.480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
68
|
Scavarda D, Major P, Lortie A, Mercier C, Carmant L. Hémisphérotomies péri-insulaires et épilepsie réfractaire pédiatrique: l'expérience de l'Hôpital Sainte-Justine de Montréal. Neurochirurgie 2007. [DOI: 10.1016/j.neuchi.2007.09.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
69
|
Crocker AG, Mercier C, Allaire JF, Roy ME. Profiles and correlates of aggressive behaviour among adults with intellectual disabilities. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH : JIDR 2007; 51:786-801. [PMID: 17803497 DOI: 10.1111/j.1365-2788.2007.00953.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
BACKGROUND Despite the heterogeneity in aggressive behaviours observed among individuals with intellectual disabilities (ID), little attention has been paid to the identification of typologies of aggression among individuals with mild or moderate ID and their associated factors. OBJECTIVE The goal of the present study was to identify profiles of aggressive behaviour and their psychosocial correlates. METHOD In this cross-sectional study of 296 adults with mild or moderate ID, information was gathered through interviews with the ID participants, their case manager and a significant other. Client files were also reviewed. RESULTS Multiple correspondence analysis followed by hierarchical cluster analysis generated six distinct profiles of aggressive behaviour in this sample. The 'violent' group clearly stood out as lacking social and vocational involvement, having more severe mental health problems, high levels of impulsivity and antisocial tendencies compared with all other groups. DISCUSSION The identification of distinct profiles of aggressive behaviour offers new possibilities for studying risk factors and eventually targeting specific risk prevention strategies.
Collapse
|
70
|
Fanciullino R, Giacometti S, Mercier C, Aubert C, Blanquicett C, Piccerelle P, Ciccolini J. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation. Br J Cancer 2007; 97:919-26. [PMID: 17848948 PMCID: PMC2360412 DOI: 10.1038/sj.bjc.6603970] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Drug resistance is a major cause of treatment failure in cancer chemotherapy, including that with the extensively prescribed antimetabolite, 5-fluorouracil (5-FU). In this study, we tried to reverse 5-FU resistance by using a double-punch strategy: combining 5-FU with a biochemical modulator to improve its tumoural activation and encapsulating both these agents in one same stealth liposome. Experiments carried out in the highly resistant, canonical SW620 human colorectal model showed a up to 80% sensitisation to 5-FU when these cells were treated with our liposomal formulation. Results with this formulation demonstrated 30% higher tumoural drug uptake, better activation with increased active metabolites including critical-5-fluoro-2-deoxyuridine-5-monophosphate, superior inhibition (98%) of tumour thymidylate synthase, and subsequently, higher induction of both early and late apoptosis. Drug monitoring showed that higher and sustained exposure was achieved in rats treated with liposomal formulation. When examined in a xenograft animal model, our dual-agent liposomal formulation caused a 74% reduction in tumour size with a mean doubling in survival time, whereas standard 5-FU failed to exhibit significant antiproliferative activity as well as to increase the lifespan of tumour-bearing mice. Taken collectively, our data suggest that resistance to 5-FU can be overcome through a better control of its intratumoural activation and the use of an encapsulated formulation.
Collapse
|
71
|
Mercier C, Scavarda D, Rossignol E, Lortie A, Carmant L. Stimulation vagale et épilepsie pédiatrique réfractaire. Étude prospective d'efficacité et de sa tolérance dans une population pédiatrique. Neurochirurgie 2007. [DOI: 10.1016/j.neuchi.2007.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
72
|
Mercier C, Ciccolini J, Dupuis C, Secq V, Padovani L, Pignon T, Dahan L, Duffaud F, Seitz J, Lacarelle B, Favre R. Prospective phenotypic screening for DPD deficiency in patients upon fluoropyrimidines administration: Impact on the reduction of drug-induced toxicities. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2541] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2541 Background: DPD deficiency is a pharmacogenetic syndrome associated with severe toxicities upon 5-FU/capecitabine intake. To detect patients at risk upon fluoropyrimidines administration we developed a simple, rapid and inexpensive phenotypic method for DPD status evaluation. Here, clinical relevance of DPD deficiency a priori determination was studied. Methods: This method was used prospectively in 50 head and neck cancers patients (60±7 years, 37M/13F). Screening for DPD deficiency was performed prior to the beginning of the platinum + 5-FU (± radiation therapy) administration. DPD status was evaluated by HPLC monitoring U/UH2 ratio levels in plasma as a surrogate marker. Only 5-FU doses were adjusted according to the level of detected impairment (mild deficiency: -20%, severe: - 50%, total: no 5-FU). Drug-induced toxicities and subsequent impact on treatment schedule were carefully monitored next for comparison with a retrospective subset of 50 patients (mean age: 58±9 years, 40M/10F), treated with standard dosage of the same chemotherapy or radio- chemotherapy schedule. Results: DPD determination permitted the detection of 11 patients with DPD impairment out of 50 (22%). These 11 patients had their 5-FU doses customized and, consequently, neither severe toxicity nor delays in the administration radiation therapy or chemotherapy were reported in this group. Conversely, 7 out of 50 (14%) patients administered with standard dosage of 5-FU displayed severe toxicities (>grade-3, WHO grading), with subsequent postponement of the following courses. One patient (2%) did not recover from his toxicities. Of these 8 patients, retrospective determination of DPD status suggested impaired function in 7 of them (87%), including the toxic- death one. Conclusions: Although non randomized, this study suggests that prospective use of DPD status has an immediate clinical benefit by, reducing the drug-induced toxicities incidence in patients treated with 5-FU, and allowing an optimal administration of several courses in a row. Our preliminary results advocate systematic DPD status screening in patients eligible for treatment with fluoropyrimidine drugs. Survival and response study still on going. No significant financial relationships to disclose.
Collapse
|
73
|
Chen L, Hachem P, Hananel A, Mu Z, Padovani L, Mercier C, Khor L, Kwon H, Ma C, Pollack A. TH-C-M100J-09: MR Guided Focused Ultrasound (MRgFU) For The Treatmentment of Prostate Cancer: A Feasibility Study of Increasing Cellular Uptake of AS-MDM2 in Vivo. Med Phys 2007. [DOI: 10.1118/1.2761657] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
74
|
Mercier C, Aballea A, Vargas CD, Paillard J, Sirigu A. Vision without Proprioception Modulates Cortico-spinal Excitability during Hand Motor Imagery. Cereb Cortex 2007; 18:272-7. [PMID: 17517681 DOI: 10.1093/cercor/bhm052] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Several studies have shown a cortico-spinal facilitation during motor imagery. This facilitation effect is weaker when the actual hand posture is incompatible with the imagined movement. To determine whether the source of this interference effect arises from online proprioceptive information, we examined transcranial magnetic stimulation (TMS)-induced motor-evoked potentials during motor imagery in the deafferented subject G.L. The patient and 7 control subjects were asked to close their eyes and imagine joining the tips of the thumb and the little finger while maintaining a hand posture compatible or incompatible with the imagined movement. Contrary to control subjects' performance, G.L.'s results show that the facilitation observed during motor imagery was independent of the hand posture. To examine how vision of the hand interacts with the imagery process, G.L. and control subjects performed the same task with the eyes open. Like control subjects, when G.L. looked at her hand, a greater facilitation was observed when her hand posture was compatible with the imagined movement than when it was incompatible. These results suggest that in the absence of proprioception, vision may facilitate or inhibit motor representations and support the idea that limb position in the brain is organized around multisensory representations.
Collapse
|
75
|
Champoux F, Paiement P, Mercier C, Lepore F, Lassonde M, Gagné JP. Auditory processing in a patient with a unilateral lesion of the inferior colliculus. Eur J Neurosci 2007; 25:291-7. [PMID: 17241290 DOI: 10.1111/j.1460-9568.2006.05260.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The role of the inferior colliculus (IC) in human auditory processing is still poorly understood. We report here the results obtained with a 12-year-old boy (FX) who suffered a very circumscribed lesion of the right IC without additional neurological damage. The child underwent an extensive battery of psychophysical hearing tests. Results revealed normal peripheral auditory functioning, bilaterally. Furthermore, masking-level differences and frequency-pattern recognition were normal for each ear. When the right ear was stimulated, behavioural tests assessing central auditory processing yielded normal results. However, when the left ear was stimulated, speech recognition in the presence of a competing ipsilateral signal and duration-pattern recognition were impaired. Similarly, performance on two dichotic speech recognition tests was poor when the target stimulus was presented in the left and the competing signal in the right ear. Finally, sound-source localization in space was deficient for speakers located on the side contralateral to the lesion. The pattern of results suggests that auditory functions such as recognition of low-redundancy speech presented monaurally, recognition of tone duration patterns, binaural separation and integration, as well as sound-source localization in space, depend on the integrity of the bilateral auditory pathways at the IC level.
Collapse
|